PWMG
HRMY icon

Prestige Wealth Management Group’s Harmony Biosciences HRMY Stock Holding History

Prestige Wealth Management Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$11K – 1110
2022
Q4 		$11K Hold
200
– – ﹤0.01% 445
2022
Q3 		$9K Hold
200
– – ﹤0.01% 431
2022
Q2 		$10K Hold
200
– – ﹤0.01% 434
2022
Q1 		$10K Buy
+200
New +$8.16K ﹤0.01% 463

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prestige Wealth Management Group's HRMY Position: Q1 2023 in Review

Prestige Wealth Management Group sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 200 shares — an estimated $11K sold.

Prestige Wealth Management Group first reported a position in HRMY in Q1 2022 and held it in 4 quarters. The position peaked at $11K in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • Prestige Wealth Management Group reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • Prestige Wealth Management Group sold 200 Harmony Biosciences shares in Q1 2023, an estimated $11K.
  • Prestige Wealth Management Group first reported a position in Harmony Biosciences in Q1 2022 and held it in 4 quarters.
  • Prestige Wealth Management Group's Harmony Biosciences position peaked at $11K in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Prestige Wealth Management Group's 13F filing for Q1 2023, filed 16 May 2023.